SABCS 2021 Interview – Symposium overview, HER2+ update, and advances with TKIs

Follow an expert in breast cancer to review the major updates from the San Antonio Breast Cancer Symposium (SABCS) 2021, including:

• SABCS 2021 overview, with top highlights and key takeaways
• Specific focus on HER2+ breast cancer, including major trial updates
• Advances in TKI use in HER2+ breast cancer, particularly those with clinical relevance

Professor Nadia Harbeck, MD, PhD, is the Scientific Director of the West German Study Group, Head of the Breast Center, and Chair for Conservative Oncology at the Department of OB&GYN at the University of Munich (LMU), Germany. In the following short interviews, she discusses what she considers the most interesting findings presented at SABCS 2021 and takes a closer look at HER2+ breast cancer and the use of tyrosine kinase inhibitors (TKIs).

SABCS 2021 top highlights and key takeaways

From major clinical trial updates in triple negative and luminal breast cancer to new information on circulating tumour DNA, Professor Harbeck gives a brief yet thorough overview of some of the main findings released at SABCS 2021.

Developments in HER2+ breast cancer

Professor Harbeck provides an expert overview of HER2+ breast cancer data from the symposium, with encouraging advances in key outcomes from several clinical trials.

Advances in using TKIs to treat breast cancer

While several TKIs are approved for use in HER2+ breast cancer, a good number of clinical trials with implications for clinical practice and patient management are discussed in this interview.

Professor Nadia Harbeck has received honoraria for lectures and/or consulting from: Amgen, AstraZeneca, Daiichi-Sankyo, Exact Sciences, Gilead, Lilly, MSD, Novartis, Pierre-Fabre, Pfizer, Roche, Sandoz, Seagen. She received an honorarium from EPG Health for participating in this interview.